1. |
李廷谦, 王刚, 王蕾. 循证医学与中药上市后的再评价[J]. 中国循证医学杂志, 2004; 4(4): 217~221.
|
2. |
胡大一, 杨进刚. 应重视上市后药物安全性的循证医学再评价--罗非昔布召回的意义[J]. 中国循证医学杂志, 2005; 5(2): 94~96.
|
3. |
Li TQ, Wang G, Wang L. Evidence-based medicine and reassessment of post-marketed Chinese herbs[J]. Chinese Journal of Evidence-based Medicine, 2004; 4(4): 217-221.
|
4. |
Farley Dixie. Benefit vs. Risk: How FDA Approves New Drugs [EB/OL]. FDA Consumer Special Report. 1995 Jan. Available from: URL: http://www.fda.gov/fdac/special/new drug/benefits.html.
|
5. |
Langley PC. Pharmacoeconomics in Drug Development and Marketing: An Overview. ISPOR Distance Learning Program. Monograph. 2004.
|
6. |
Langley PC. Pharmacoeconomics in Market Entry and Market Support. ISPOR Distance Learning Program. Monograph. 2004.
|
7. |
Hu DY, Yang JG. Evidence-Based safety reassessment of post-marketed drug-important of recall of Refecoxib[J]. Chinese Journal of Evidence-based Medicine, 2005; 5(2): 94-96.
|
8. |
Barden J, Edwards JE, McQuay HJ, Moore RA. Single Dose Oral Celecoxib for Postopreative Pain (Cochrane Reviw). In: The Cochrane Library, Issue 1, 2005. Chichester, UK: John Wiley & Sons, Ltd.
|
9. |
Barden J, Edwards J, Moore RA, McQuay HJ. Single Dose Oral Rofecoxib for Postoperative Pain (Cochrane Reviw). In: The Cochrane Library, Issue 1, 2005. Chichester, UK: John Wiley & Sons, Ltd.
|
10. |
Jackson CM, Lipworth B. Benefit-risk assessment of long-acting beta2-agonists in asthma[J]. Drug Saf, 2004; 27(4): 243-270.
|